leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 10:36:15 - browse：42

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Why failed clinical trials don’t always spell doom for a new drug

hotspot

WSS

South Korea throws huge K

3 hurdles to bringing medical devices to the U.S. market

Weight bias in eating disorder treatment complicated by new weight loss drugs

Methadone doses haven’t kept up in the age of fentanyl

Colonoscopy at 40? Study finds a possible benefit

Why failed clinical trials don’t always spell doom for a new drug

focus

leisure time

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

The battle over the Brookhaven Landfill on Long Island

BioMarin wins approval for gene therapy to treat hemophilia A

Colonoscopy at 40? Study finds a possible benefit

State Dept. review finds Biden bears some blame for Afghanistan failures

Death of patient in Alzheimer’s trial raises question of possible risks

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Colonoscopy at 40? Study finds a possible benefit

In Memoriam: Notable people who died in 2023

In same hospitals, Black patients receive fewer opioids than white patients

hotspot

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

A biotech analyst on neuroscience, placebo effect, not over

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Why are elite athletes different? Take a look at their microbes

The story of mRNA: From a loose idea to a tool that may help curb Covid

A biotech analyst on neuroscience, placebo effect, not over

hotspot

hotspot

knowledge

leisure time